Additionally, in patients with non-D2T RA, there were no significant differences in drug discontinuation rates for each b/tsDMARD (p = 0.47), but drug switching rates differed in the order of rituximab, JAK inhibitors, tocilizumab, abatacept, and TNF inhibitors (p < 0.001). This evidence concerns the gene TNF and rheumatoid arthritis.